LXRX Lexicon Pharmaceuticals Inc

Price (delayed)

$4.64

Market cap

$669.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.06

Enterprise value

$583.97M

Highlights
LXRX's debt has dropped by 95% year-on-year
Lexicon Pharmaceuticals's quick ratio has increased by 11% from the previous quarter and by 4.3% YoY
Lexicon Pharmaceuticals's equity has surged by 178% YoY but it has decreased by 2.4% QoQ
The net income has plunged by 115% YoY but it has soared by 78% from the previous quarter
LXRX's revenue has plunged by 95% YoY and by 33% from the previous quarter
The company's gross profit has shrunk by 95% YoY and by 34% QoQ

Key stats

What are the main financial stats of LXRX
Market
Shares outstanding
144.39M
Market cap
$669.96M
Enterprise value
$583.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.39
Price to sales (P/S)
41.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.45
Earnings
Revenue
$16.02M
EBIT
-$3.34M
EBITDA
-$1.28M
Free cash flow
-$135.19M
Per share
EPS
-$0.06
Free cash flow per share
-$0.94
Book value per share
$1.06
Revenue per share
$0.11
TBVPS
$1.04
Balance sheet
Total assets
$193.26M
Total liabilities
$40.71M
Debt
$11.66M
Equity
$152.55M
Working capital
$106.42M
Liquidity
Debt to equity
0.08
Current ratio
3.73
Quick ratio
3.63
Net debt/EBITDA
67.39
Margins
EBITDA margin
-8%
Gross margin
91.5%
Net margin
-80.6%
Operating margin
-38.7%
Efficiency
Return on assets
-5.8%
Return on equity
-13.4%
Return on invested capital
-3.7%
Return on capital employed
-2.2%
Return on sales
-20.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LXRX stock price

How has the Lexicon Pharmaceuticals stock price performed over time
Intraday
-2.11%
1 week
-4.72%
1 month
8.16%
1 year
150.81%
YTD
35.67%
QTD
-20.95%

Financial performance

How have Lexicon Pharmaceuticals's revenue and profit performed over time
Revenue
$16.02M
Gross profit
$14.66M
Operating income
-$6.2M
Net income
-$12.92M
Gross margin
91.5%
Net margin
-80.6%
The net income has plunged by 115% YoY but it has soared by 78% from the previous quarter
The operating income has dropped by 106% year-on-year but it has surged by 87% since the previous quarter
LXRX's revenue has plunged by 95% YoY and by 33% from the previous quarter
The company's gross profit has shrunk by 95% YoY and by 34% QoQ

Growth

What is Lexicon Pharmaceuticals's growth rate over time

Valuation

What is Lexicon Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.39
P/S
41.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.45
The company's EPS has shrunk by 108% YoY but it has surged by 89% QoQ
Lexicon Pharmaceuticals's equity has surged by 178% YoY but it has decreased by 2.4% QoQ
LXRX's price to sales (P/S) is 126% more than its last 4 quarters average of 18.4
LXRX's revenue has plunged by 95% YoY and by 33% from the previous quarter

Efficiency

How efficient is Lexicon Pharmaceuticals business performance
The company's return on sales has shrunk by 167% YoY but it has surged by 89% QoQ
LXRX's ROA has shrunk by 125% YoY but it has soared by 73% QoQ
LXRX's ROIC has plunged by 115% YoY but it has soared by 84% from the previous quarter
The company's return on equity has shrunk by 111% YoY but it has surged by 84% QoQ

Dividends

What is LXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LXRX.

Financial health

How did Lexicon Pharmaceuticals financials performed over time
LXRX's total liabilities has dropped by 87% year-on-year and by 14% since the previous quarter
The total assets has declined by 48% year-on-year and by 5% since the previous quarter
LXRX's debt is 92% smaller than its equity
Lexicon Pharmaceuticals's equity has surged by 178% YoY but it has decreased by 2.4% QoQ
Lexicon Pharmaceuticals's debt to equity has shrunk by 98% YoY but it has increased by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.